EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with nearly one quarter of patients presenting with metastatic disease at diagnosis. The epidermal growth factor receptor (EGFR) plays a central role in CRC pathogenesis through activation of downstream RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways, and has become a major therapeutic target. Anti-EGFR monoclonal antibodies, cetuximab and panitumumab, have demonstrated survival benefit in selected patients, particularly those with left-sided, RAS wild-type tumors. However, primary and acquired resistance limit their efficacy, underscoring the need for predictive biomarkers and novel strategies. This review synthesizes current knowledge of EGFR biology, therapeutic integration, and biomarker development, including RAS and BRAF mutations, MSI status, HER2 amplification, EGFR ligands (AREG/EREG), consensus molecular subtypes, and liquid biopsy applications. We also discuss mechanisms of resistance such as pathway reactivation, receptor mutations, and epithelial-to-mesenchymal transition, alongside emerging approaches, including combination regimens, ctDNA-guided rechallenge, and genotype-specific inhibitors. Collectively, these insights highlight the evolving landscape of precision oncology in CRC and the importance of molecular stratification to optimize EGFR-targeted therapy and overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remaining trials evaluated trastuzumab with lapatinib/pertuzumab/tucatinib, which also showed responses to HER2-positive mCRC [33,80].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35,36,37].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Studies such as CRICKET and CAVE showed that restarting the same therapy in carefully selected patients can lead to increased overall survival and ORR [33].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Beyond bypass loops, mutations in the extracellular domain of EGFR (EGFR-ECD mutation), such as the S492R mutation, can change the receptor shapes, which in turn prevents cetuximab binding [33,34].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“The CRYSTAL trial highlighted that the combination of cetuximab with FOLFIRI improved PFS and overall response rate [33].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [33]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064 · cited 1×
“Colorectal cancer (CRC) ranks third in incidence with 1.9 million new cases, and ranks third in mortality during the year 2022, and around 24% of the cases present with de novo metastatic disease [1–3].”
InfluentialEpithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628 · cited 1×
“EMT is a complicated process where epithelial cells transform and acquire mesenchymal characteristics [99,100].”
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“CMS2 (canonical/epithelial) tumors, characterized by WNT and MYC pathway activation, are highly EGFR dependent and consistently derive substantial benefit from anti-EGFR therapy [69,70].”
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“The pivotal BOND trial demonstrated improved response rates and survival with cetuximab [33], while early panitumumab studies confirmed activity in heavily pretreated patients [34].”
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 4×
“…and progression-free survival (PFS) (median PFS, 8.9 vs. 8.0 months; hazard ratio, 0.85; 95% CI, 0.72 to 0.99; p = 0.048) compared to FOLFIRI alone [5], while the PRIME trial demonstrated that panitumumab plus FOLFOX significantly prolonged PFS over FOLFOX alone (median PFS, 9.6 vs. 8.0 months;…”
InfluentialVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288 · cited 1×
“These receptors mediate changes in vascular proliferation and permeability [120].”
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060 · cited 1×
“Colorectal cancer (CRC) ranks third in incidence with 1.9 million new cases, and ranks third in mortality during the year 2022, and around 24% of the cases present with de novo metastatic disease [1–3].”
InfluentialOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · cited 1×
“Their high mutational burden and frequent subclonal resistance drivers make immune checkpoint inhibitors the preferred option, positioning MSI status as a strong negative predictive biomarker [55].”
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“This mutation leads to activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which results in uncontrollable cell proliferation [95] (Figure 2).”
Cited by
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Studies such as CRICKET and CAVE showed that restarting the same therapy in carefully selected patients can lead to increased overall survival and ORR [33].”
InfluentialDoes the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?
Raeesian, N., & Riese, D. J. (2026) · Biomolecules · doi:10.3390/biom16081079
Raut, R., Anwar, S., Alromaihi, R. A., & Alrumaihi, F. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080807
Kwiatkowska, L., & Szczuko, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177559
“Therefore, before incorporating this therapeutic strategy, it is essential to assess both the molecular status and the tumor location [42].”
Gao, J.-M., Yan, W., Yang, J., Ren, H., Zhao, L., Zhang, Y., Chen, Y., Zhou, J., Wei, Z.-Z., Liu, Q., et al. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.129000
Metadata
- Authors
- Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A.
- Affiliations
- American University of Beirut Medical Center (LB)
- Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon
- Corresponding author
- Shamseddine, Ali
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-04-03
- Volume
- 27
- Issue
- 7
- Pages
- 3265
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13072906
- OpenAlex
- W7149929304
- Cited by
- 4
- References
- 135
- Citations by year
- 2026: 4
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- colorectal cancer, EGFR signaling, anti-EGFR monoclonal antibody, cetuximab, panitumumab, treatment resistance, predictive biomarkers, RAS mutations, BRAF mutation, microsatellite instability, HER2 amplification, EGFR ligands, consensus molecular subtypes, liquid biopsy, combination therapy, precision oncology, RAS/MAPK pathway, PI3K/AKT/mTOR pathway, epithelial-mesenchymal transition, molecular stratification
- MeSH terms
- Antineoplastic Agents, Immunological, Humans, Mutation, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. https://app.cochat.ai/papers/10.3390/ijms27073265
- The paper
- Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026). EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.